Current challenges in therapy of myelodysplastic syndromes

Current Opinion in Hematology

Volumn 10, Issue 1, 2003, Pages 60-67

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; AZACITIDINE; CYTARABINE; ERYTHROPOIETIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; THALIDOMIDE DERIVATIVE; THYMOCYTE ANTIBODY; TIPIFARNIB; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL; HIGH RISK PATIENT; HUMAN; KARYOTYPE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL TRANSPLANTATION;

ALGORITHMS; ANTINEOPLASTIC AGENTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 0037215408     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200301000-00010     Document Type: Review

References (28)

1. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. Most widely used system to assess prognosis in myelodysplastic syndrome
3. Jaffe ES, Harris NL, Stein H, et al. (eds): Myelodysplastic syndromes. In World Health Organization Classification of Tumors: Pathology and Genetics: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001:63-73.
4. Cheson BD, Bennett JM, Kantarjian H, et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674. Makes the reader aware of great variety of response criteria used in the past and consequent difficulty in comparing results
5. Anderson JE, Appelbaum FR, Schoch G, et al.: Allogeneic marrow transplantation for refractory anemia: A comparison of two preparative regimens and analysis of prognostic factors. Blood 1996, 87:51-58. Together with [25•], provides results of allogeneic transplantation in myelodysplastic syndrome at Fred Hutchinson Center in Seattle. Whether results would be similar at smaller centers is an important question
6. Hellstrom-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67-71.
7. Hellstrom-Lindberg E, Ahlgrem T, Begguin Y, et al.: Treatment of the anemia of myelodysplastic syndromes with G-CSF plus erythropoietin: Results from a randomized phase II study and long term follow-up on 71 patients. Blood 1998, 92:68-75.
8. Negrin RS, Stein R, Doherty K, et al.: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human G-CSF plus erythropoietin: Evidence for in vivo synergy. Blood 1996, 87:4076-4081.
9. Kurzrock R, Cortes J, Thomas DA, et al.: Pilot study of low-dose Interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001, 19:4165-4172.
10. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965.
11. Thomas DA, Kantarjian HM: Current role of thalidomide in cancer treatment. Curr Opin Oncol 2000, 12:564-573.
12. Silverman LR, Demakos EP, Peterson BL, et al.: Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 2002, 20:2429-2440. Results, and accompanying editorial, suggest that azacitidine might be considered standard of care for myelodysplastic syndrome. A different view is presented in the current article
13. Kornblith Alice B, Herndon JE II, Silverman LR, et al.: Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 2002, 20:2441-2452.
14. Beaupre DM, Kurzrock R: RAS and leukemia: From basic mechanisms to gene-directed therapy. J Clin Oncol 1999, 17:1071.
15. Karp JE, Lancet JE, Kaufmann SH, et al.: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase I clinical-laboratory correlative trial. Blood 2001, 97:3361-3369.
16. Kurzrock R, Cortes J, Ryback ME, et al.: Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome [abstract]. Blood 2001, 98:848a.
17. Molldrem JJ, Caples M, Mavroudis D, et al.: Antihymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
18. Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al.: Hematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-CM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314-1322.
19. List AF, Brasfield F, Heaton R, et al.: Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. Blood 1997, 90:3364-3369.
20. Estey E, Thall P, Beran M, et al.: Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997, 90:2969-2977. Raises questions about the wisdom of regarding myelodysplastic syndrome and AML as largely separate entities
21. Anderlini P, Pierce S, Kantarjian H, et al.: Acute myeloid leukemia-type chemotherapy for myelodysplasia. J Clin Oncol 1996, 14:1404-1405. Questions whether transplant is the only curative therapy for myelodysplastic syndrome
22. Estey E: Therapeutic options for acute myelogenous leukemia. Cancer 2001, 92:1059-1073.
23. Estey EH, Thall PF, Cortes JE, et al.: Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-c-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood 2001, 98:3575-3583.
24. Gilliland DG, Griffin JD: Role of FLT3 in leukemia. Curr Opin Hematol 2002, 9:274-281.
25. Anderson JE, Appelbaum FR, Fisher L, et al.: Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood 1993, 82:677-681. See [5•]
26. Giralt S, Estey E, Albitar M, et al.: Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
27. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduetion for the treatment of malignant and non-malignant hematologic diseases. Blood 1998, 91:756-763.
28. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97;3390-3400. Current perspective on minitransplants